Paul dives into the debate surrounding choline, TMAO, and cardiovascular risk, shedding light on the lack of human studies establishing a concrete link. He challenges the assumption of causality based on associations, emphasizing the complexity of factors influencing TMAO levels and their relationship to health issues like kidney disease and cardiovascular conditions.
